Dr Tido VON SCHOEN-ANGERER

Dr Tido VON SCHOEN-ANGERER

  • Centre Médical de La Chapelle

Spécialités

Médecine anthroposophique, Pédiatrie , membre FMH

Langues

français, allemand, arménien, suédois, anglais

+41 22 827 25 25 info@cmlachapelle.ch

En savoir plus

Expérience

2013

Chef de clinique adjoint, pédiatrie, hôpital fribourgeois - HFR, Fribourg, Suisse

1999-2012

Médecins Sans Frontières (MSF)

2006-2012

Directeur Exécutif, Campagne pour l' accès aux Médicaments Essentiels (CAME), Genève

2005-2006

Coordinateur Recherche et Développement (R&D), Campagne pour l' Accès aux Médicaments Essentiels, Berlin

2004-2005

Directeur des opérations, Berlin, Allemagne

2001-2004

Chef de mission, Arménie et Nagorny Karabakh

1991-1993

Coordinateur du projet VIH, Thaïlande
Formation

2014

Diplôme en médecine d'orientation anthroposophique, Gesellschaft anthroposophischer Arzte in Deutschland GAAD

2009

Master en Sante Publique (management des systèmes de santé) MPH, London School of Hygiene and Tropical Medicine

1999

Spécialiste en pédiatrie, certification : American Board of Pediatrics

1996

Licences de pratique médicale: «Approbation» (Allemagne), « legitemerad lakare » (Suède)

1995

Diplôme de Sante Publique pour les pays en voie de développement, Université Uppsala, Suède

1994

Diplôme de Médecine MD, Université Uppsala, Suède
Comités et conseils d’administration
  • UNITAID : Conseil d'administration (représentant la société civile). 2011-2014
  • OMS : 'WHO Task Force for New Drug Policy Development for TB'. 2012-2013
  • OMS : 'WHO TB Strategic and Technical Advisory Group'. 2009-2012
  • OMS : Expert au groupe de travail intergouvernemental sur la sante publique, l'innovation et la propriété intellectuelle. 2006-2007
Publications
  1. von Schoen-Angerer T, Goyert A, Vagedes J, Kiene H, Merckens H, Kienle GS. Case report: Disappearance of an advanced adenomatous colon polyp after intratumoral injection with Viscum album. J Gastrointestin Liver Dis. 2014 23(4):449-52
  2. von Schoen-Angerer T, Wilkens J, Kienle GS, Kiene H, Vagedes J. High-dose Viscum album extract treatment in the prevention of recurrent bladder cancer: a retrospective case series. Submitted for publication
  3. von Schoen-Angerer T, Madeleyn R, Kienle GS, Kiene H, Vagedes J. Viscum album in the treatment of a girl with refractory childhood absence epilepsy. J Child Neural 20014: pii: 0883073814541473.
  4. Michaelis R, Andrews D, Reiter JM, von Schoen-Angerer T. Resolving cognitive dissonance by acquisition of self-organizational skills may decrease drug-resistant seizures - A case report. Epilepsy Behav Case Rep 2014 (2): 64-66
  5. von Schoen-Angerer T. Learning all the lessons: Expanding access to malaria diagnosis and treatment. J Public Health Policy. 2013 Mar 28. doi: 10.1057 /jphp.2013.15
  6. von Schoen-Angerer T, Cohn J, Swan T, Piot P. UNIT AID can address HCV /HIV co-infection. Lancet. 2013 Feb 23;381 (9867):628.
  7. Hogerzeil HV, Liberman J, Wirtz VJ, Kishore SP, Selvaraj S, Kiddell-Monroe R, Mwangi-Powell FN, von Schoen-Angerer T. Promotion of access to essential medicines for Non-Communicable Diseases: practical implications of the UN political declaration. Lancet. 2013 Feb 23;381(9867):680-9
  8. Cohn J, von Schoen-Angerer T, Jambert E, Arreghini G, Childs M. When falsified medicines enter the supply chain: Description of an incident in Kenya and lessons learned for rapid response. J Pub Health Policy, 2012 Nov 22. doi: 10.1057 /jphp.2012.53
  9. van Schoen-Angerer T, Ford N, Arkinstall J. Access to Medicines in Resource-Limited Settings: The End of a Golden Decade? Global Adv Health Med. 2012; 1 (1): 50-57
  10. Ford N, Singh K, Cooke G, Mills EJ, van Schoen-Angerer T, Kamarulzaman, du Cros P. Expanding Access to Treatment for Hepatitis C in Resource-Limited Settings: Lessons from HIV/AIDS. Clin Infect Dis. 2012 May;54(10):1465-72
  11. Moon S, Jambert E, Childs M, van Schoen-Angerer T. A win-win solution? A critical analysis of tiered pricing to improve access to medicines in developing countries. Global Health. 2011 Oct 12;7(1 ):39.
  12. Maher D, van Schoen-Angerer T, Cohn J. Crunch time for funding of universal access to antiretroviral treatment for people with HIV infection. Int J Clin Pract. 2011 Aug;65(8):824-7.
  13. Cox H, Ford N, Keshavjee S, McDermid C, von Schoen-Angerer T, Mitnick C, Goemaere E. Rational use of moxifloxacin for tuberculosis treatment. Lancet Infect Dis. 2011 (4):259-60
  14. Arkinstall J, Childs M, Menghaney L, Ford N, van Schoen-Angerer T. How European policies risk harming access to generic medicines. J Generic Medicines, 2011, 8 (1 ): 14-22
  15. van Schoen-Angerer T. Putting patients above politics. Lancet. 2010 Oct 16;376(9749):1301-2.
  16. Neely M, Decosterd L, Fayet A, Lee JS, Margot A, Kanani M, di lulio J, von Schoen-Angerer T, Jelliffe R, Calmy A. Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers. Antimicrob Agents Chemother. 2010 Nov;54(11):4619-25.
  17. Moon S, Perez Casas C, Kindermans JM, de Smet M, von Schoen-Angerer T. Focusing on quality patient care in the new global subsidy for malaria medicines. PLoS Med. 2009 Jul 21;6(7):e1000106.
  18. Calmy A, Pizzocolo C, Pizarro L, Brucker G, Murphy R, Katlama C et al; Strategies in Resource-Limited Settings Working Group. The marriage of science and optimized HIV care in resource-limited settings. AIDS. 2008 Nov 12;22(17):2227-30.
  19. Roey J, van Schoen-Angerer T, Ford N, Calmy A. How developing world concerns need to be part of drug development plans: a case study of four emerging antiretrovirals. Drug Discov Today. 2008 Jul;13(13-14):601-5.
  20. van Schoen-Angerer T, Shepherd S, Lokuge K, Mills C, Fournier C. Kwashiorkor and severe acute malnutrition in childhood. Lancet. 2008 May 24;371 (9626):1748-9.